Skip to Main Content
Don't have an account? Create Account
FILTER WITHIN THIS TAG ››
Action
Quality
Education
Institute
Reset
Loading more articles
340B Drug Pricing Program

Learn about the recently proposed Medicare rules that will broaden the scope of cuts to hospitals in the 340B Drug Pricing Program and to off-campus hospital outpatient departments.

view more »
340B Drug Pricing Program

Congress is expected to consider legislation to combat the opioid epidemic, fund the Department of Health and Human Services, and enable federal response to pandemic threats.

view more »
340B Drug Pricing Program

The Centers for Medicare & Medicaid Services has released Outpatient Prospective Payment System and Physician Fee Schedule proposed rules for calendar year 2019 that would expand site-neutral payment policies and continue Medicare Part B drug payment cuts to 304B hospitals.

view more »
340B Drug Pricing Program

A new proposed rule for Medicare’s Outpatient Prospective Payment System would broaden the scope of cuts to hospitals in the 340B Drug Pricing Program and to off-campus provider-based departments; it also contains provisions related to quality reporting and transparency.

view more »
340B Drug Pricing Program

America’s Essential Hospitals and the other plaintiffs are coordinating next steps and plan to promptly refile the case in district court.

view more »
340B Drug Pricing Program

The American Hospital Association, the Association of American Medical Colleges, and America’s Essential Hospitals expressed disappointment that the courts once again failed to rule on merits of the 340B case and vowed to continue the fight to reverse these unwarranted cuts.

view more »
340B Drug Pricing Program

Hospitals will have until Sept. 12 to complete the recertification process through the Office of Pharmacy Affairs Information System.

view more »
340B Drug Pricing Program

A Government Accountability Office witness and several 340B Drug Pricing Program stakeholders testified last week at a House committee hearing; another House committee marked up several consumer-driven health care bills.

view more »
340B Drug Pricing Program

The July 11 hearing will focus on contract pharmacies and a slate of 15 bills and discussion drafts related to the program; two essential hospital leaders will testify.

view more »
340B Drug Pricing Program

We encourage our members to urge their representatives on the House Energy & Commerce Committee to support essential hospitals at a 340B hearing on July 11.

view more »
340B Drug Pricing Program

A new bill by Rep. Chris Collins (R-NY) would impose a user fee for hospitals participating in the 340B Drug Pricing Program; a House subcommittee marked up hospital preparedness and graduate medical education bills.

view more »
340B Drug Pricing Program

Modeled on a program developed at essential hospital St. Joseph's Regional Medical Center, in Paterson, N.J., the Alternatives to Opioids bill is one of 25 opioid-related bills the House passed last week.

view more »
340B Drug Pricing Program

The bill would bring relief to essential hospitals and their patients from damaging Medicare outpatient payment cuts and much-needed accountability for manufacturers in the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

The House aims to complete voting by the July Fourth recess, but Senate work on opioid legislation likely will continue into August amid a shortened recess.

view more »
340B Drug Pricing Program

This is the latest of several delays of a rule that provides guidance on the calculation of ceiling prices and imposes civil monetary penalties on manufacturers who knowingly exceed them.

view more »
340B Drug Pricing Program

The delay enables manufacturer overcharges that jeopardize access to affordable drugs for vulnerable patients and drive up costs for hospitals.

view more »
340B Drug Pricing Program

Senate Democrats sharply questioned the repeated delays of a final rule on drug ceiling prices and manufacturer civil monetary penalties; The House continues to focus on passing an opioid package.

view more »
340B Drug Pricing Program

The association urged the Health Resources and Services Administration to immediately implement a final rule establishing the calculation of ceiling prices and imposing manufacturer civil monetary penalties.

view more »
340B Drug Pricing Program

House leadership remains focused on passing a bipartisan opioid-related legislative package by Memorial Day, but recently indicated a June vote might be more likely.

view more »
340B Drug Pricing Program

The plan cites and builds on proposed changes to the 340B Drug Pricing Program in the president’s fiscal year 2019 budget, as well as damaging cuts implemented through the calendar year 2018 Outpatient Prospective Payment System final rule.

view more »
340B Drug Pricing Program

The proposal would delay by an additional year implementation of a final rule on ceiling prices and manufacturer civil monetary penalties in the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

Four House hearings this week examine the opioid crisis, as lawmakers work to craft bipartisan legislation; A Senate hearing focuses on oversight reports on the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

The decision to delay rules to safeguard patients and hospitals from drug company overcharges is unacceptable and undermines the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

On May 4, America’s Essential Hospitals and fellow plaintiffs will make oral arguments in a legal battle to reverse damaging Medicare cuts to hospitals in the 340B Drug Pricing Program; The public can watch via livestream.

view more »
340B Drug Pricing Program

The Centers for Medicare & Medicaid Services offers details on how Medicare Advantage plans might be affected by reimbursement reductions in the calendar year 2018 Outpatient Prospective Payment System final rule.

view more »
340B Drug Pricing Program

House Republicans this week hope to bring to the floor a bill to fund the government through the remainder of the fiscal year; America's Essential Hospitals CEO asked to testify during Senate committee hearing on 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

Even with its long record of success, the 340B program still faces undue scrutiny, distorted and misleading claims, and demands for onerous new reporting.

view more »
340B Drug Pricing Program

The budget plan for fiscal years 2018 and 2019 proposes changes to the distribution of 340B Drug Pricing Program savings and increased funding to fight the opioid crisis.

view more »
340B Drug Pricing Program

The nation’s safety net cannot sustain the dramatic cuts in this proposal to Medicare, Medicaid, and other social programs on which low-income working Americans and their families depend.

view more »
340B Drug Pricing Program

This badly misleading report makes no attempt to focus on or isolate the 340B drug payment policy. Rather, it masks the policy's damaging impact by conflating it with other unrelated policy changes.

view more »
340B Drug Pricing Program

America’s Essential Hospitals continues to fight to protect the 340B Drug Pricing Program, a crucial source of support for essential hospitals. Participants heard an overview of our recent advocacy activities and an update on our next steps.

view more »
340B Drug Pricing Program

Congress returns from recess to focus on long-term solutions after passing a short-term bill to fund the government through Jan. 19; lawmakers push for delay of 340B Drug Pricing Program cuts.

view more »
340B Drug Pricing Program

District court judge finds that the lawsuit was premature, but he does not rule on the merits of the claim by America's Essential Hospitals, the American Hospital Association, and the Association of American Medical Colleges.

view more »
340B Drug Pricing Program

While Congress grapples with competing priorities, legislative efforts to stop cuts to Medicare payments for the 340B Drug Pricing Program continue. America's Essential Hospitals urges all association members to contact their delegations today.

view more »
340B Drug Pricing Program

The new document details the use of two Medicare outpatient, claims-based modifiers hospitals will be required to report, starting Jan. 1, for drugs purchased through the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

Republican leaders hope to introduce the final tax reform bill early next week; a bill to stop cuts to the 340B Drug Pricing Program has 130 cosponsors.

view more »
340B Drug Pricing Program

Tax reform legislation heads to a House-Senate conference committee. Meanwhile, a bill to delay Medicaid disproportionate share hospital payment cuts could be included in year-end legislation.

view more »
340B Drug Pricing Program

America's Essential Hospitals urges all association members to call their House delegations today and urge them to cosponsor H.R. 4392, a bill that would halt enforcement of a damaging new Medicare policy that cuts Part B payments for 340B drugs by 27 percent.

view more »
340B Drug Pricing Program

The legislative priorities include a health care extenders package, tax reform, and a long-term funding bill. Also, bipartisan House legislation to halt 340B payment cuts now has more than 50 cosponsors.

view more »
340B Drug Pricing Program

Hospitals that contract with or are owned by state or local government must now identify a government official to attest to the hospital's classification.

view more »
340B Drug Pricing Program

America's Essential Hospitals urges all association members to contact their House delegations today and ask them to cosponsor H.R. 4392, a bill that would place a permanent moratorium on a new Centers for Medicare & Medicaid Services cut to 340B hospitals.

view more »
340B Drug Pricing Program

America's Essential Hospitals thanks Reps. David McKinley (R-WV) and Mike Thompson (D-CA) for legislation that would place a permanent moratorium on the Centers for Medicare & Medicaid Services policy to cut $1.6 billion in Medicare Part B drug reimbursement from 340B hospitals.

view more »
340B Drug Pricing Program

The lawsuit argues that the 340B provisions of the Centers for Medicare & Medicaid Services’ outpatient prospective payment system rule violate the Social Security Act and should be set aside under the Administrative Procedure Act as unlawful and in excess of the HHS Secretary’s statutory authority.

view more »
340B Drug Pricing Program

America’s Essential Hospitals is closely reviewing the final rules and pursuing strategies to protect our members from these devastating cuts. Key aspects of the recently released final rules are summarized in this Action Update.

view more »
340B Drug Pricing Program

Dive into the policy details of the CMS rule that cuts 340B program savings, and hear how America’s Essential Hospitals plans to respond.

view more »
340B Drug Pricing Program

Due to technical difficulties, the new 340B recertification period will run through Dec. 6; hospitals that already started the process must restart.

view more »
340B Drug Pricing Program

The rule cuts 340B Drug Pricing Program payments by $1.6 billion and requires hospitals to use modifiers to identify 340B drugs in Medicare claims.

view more »
340B Drug Pricing Program

The final rule's cuts to Medicare Part B drug payments to 340B hospitals jeopardizes health care access for millions of low-income individuals and families nationwide and weakens the ability of essential hospitals to provide vital services to communities.

view more »
340B Drug Pricing Program

Hospitals will have until Nov. 21 to complete the recertification process through the new Office of Pharmacy Affairs Information System.

view more »
340B Drug Pricing Program

The harmful payment reduction was included in the 2018 Outpatient Prospective Payment System proposed rule, expected to be finalized this fall.

view more »
340B Drug Pricing Program

The most recent delay to July 2018 comes after the Health Resources and Services Administration issued a proposed rule seeking feedback from stakeholders.

view more »
340B Drug Pricing Program

Providers can register a new entity or contract pharmacy through the 340B Office of Pharmacy Affairs Information System through Oct. 16.

view more »
340B Drug Pricing Program

The component enables manufacturers and covered entities to register for the 340B Drug Pricing Program, participate in annual recertification, and communicate with the Office of Pharmacy Affairs on pending tasks.

view more »
340B Drug Pricing Program

A push is underway on Capitol Hill to delay Medicaid disproportionate share hospital cuts and withdraw proposed 340B policy. Please urge your member of Congress to sign both letters.

view more »
340B Drug Pricing Program

Unless another delay is secured, Medicaid disproportionate share hospital payments will be cut by $2 billion beginning in fiscal year 2018, escalating to $8 billion by 2024.

view more »
340B Drug Pricing Program

The meeting came a day after the association submitted comments to the agency in response to the proposed annual update of the Hospital Outpatient Prospective Payment System.

view more »
340B Drug Pricing Program

Congress aims to pass legislation by Sept. 30 to stabilize the Affordable Care Act (ACA) insurance markets and reauthorize several health care programs; three senators plan to unveil new ACA repeal legislation.

view more »
340B Drug Pricing Program

The Sept. 13 webinar for covered entities will focus on the registration component of the new Office of Pharmacy Affairs Information System.

view more »
340B Drug Pricing Program

By cutting reimbursement rates for Part B drugs to 340B hospitals, the Centers for Medicare & Medicaid Services would harm essential hospitals, which care for the nation’s poorest, most complex, and costliest patients.

view more »
340B Drug Pricing Program

The Health Resources and Services Administration is seeking comments on whether to further delay implementation of a final rule on ceiling prices and civil monetary penalties in the 340B Drug Pricing Program by nine months.

view more »
340B Drug Pricing Program

The system will be unavailable from Aug. 15 until mid-September; hospitals are urged to verify contact information for authorizing officials and primary contacts in the system before Aug. 14.

view more »
340B Drug Pricing Program

The delay allows for implementation of a new online tool that will allow providers to register and recertify 340B sites and contract pharmacies.

view more »
340B Drug Pricing Program

The latest from experts on the CMS proposed policy rules that cut 340B savings and support for outpatient services in underserved areas.

view more »
340B Drug Pricing Program

The proposed rule would increase outpatient payment rates by 1.75 percent and drastically reduce Medicare Part B reimbursement for drugs purchased through the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

Attendees gained a comprehensive view of legislative and regulatory action in Washington, D.C, a preview of action in the fall, and our recommendations for messaging and strategy during Congress’ August recess.

view more »
340B Drug Pricing Program

A group of Republican and Democratic governors sent a letter to Senate leadership encouraging a bipartisan approach to repealing the Affordable Care Act.

view more »
340B Drug Pricing Program

The committee’s intentions remain unclear; we recommend essential hospitals prepare to publicly describe what auditors found and corrective actions taken.

view more »
340B Drug Pricing Program

The final rule on drug ceiling prices and manufacturer civil monetary penalties under the 340B Drug Pricing Program now will go into effect on Oct. 1.

view more »
340B Drug Pricing Program

The policy team at America's Essential Hospitals discussed the regulatory outlook for the next year, including key policy issues on the horizon.

view more »
340B Drug Pricing Program

HRSA has delayed until March 21 the effective date of a final rule on drug ceiling prices and manufacturer civil monetary penalties in the 340B program.

view more »
340B Drug Pricing Program

The Feb. 7 letter offers recommendations on proposed executive orders, regulations, and legislation that could affect essential hospitals, patients.

view more »
340B Drug Pricing Program

The decision preserves the 340B program’s valuable benefits to low-income and other disadvantaged people, and the hospitals on which they depend.

view more »
340B Drug Pricing Program

A memo instructs all executive departments and agencies to temporarily halt pending regulations until incoming department or agency heads can review them.

view more »
340B Drug Pricing Program

The regulation makes "penny pricing" final and sets fines of up to $5,000 per instance of a manufacturer overcharging providers for covered medications in the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program

In this webinar we looked back at the 2016 advocacy landscape, discussed the progress we have made on key issues affecting essential hospitals, reviewed our interaction with the Trump transition team, and looked forward to 2017. Webinar Recording

view more »
340B Drug Pricing Program

Under the rule, CMS would increase the OPPS payment rate by 1.65 percent and provide flexibility in the meaningful use of EHRs, among other things.

view more »
340B Drug Pricing Program

Join us to discuss the policies, outlined by CMS, for the implementation of the site neutral law.

view more »
340B Drug Pricing Program

CMS provides more flexibility than previously proposed, ensuring non-grandfathered, off-campus hospital outpatient departments will be reimbursed in 2017.

view more »
340B Drug Pricing Program
340B Drug Pricing Program

Hospitals eligible for the essential community providers list are participants in the 340B and DSH programs, critical access hospitals, and others.

view more »
340B Drug Pricing Program

Hospitals must complete recertification of their compliance with all requirements of the 340B program. Failure to do so results in removal from the program.

view more »
340B Drug Pricing Program

HRSA is proposing that a decision-making body within the Department of Health and Human Services be responsible for reviewing claims and resolving deputes.

view more »
340B Drug Pricing Program

CMS recently proposed policies for implementing the site neutral law – join us July 26 to discuss the impacts this will have on your hospital.

view more »
340B Drug Pricing Program

This week, the Senate votes on the Comprehensive Addiction and Recovery Act. Last week, the House passed a mental health bill in a bipartisan vote.

view more »
340B Drug Pricing Program

The proposed rule would implement Section 603 of the Bipartisan Budget Act, which reduced payments for new, off-campus hospital outpatient departments.

view more »
340B Drug Pricing Program

The event, from 1 - 2 pm ET, will include important information on the annual recertification process and best practices.

view more »
340B Drug Pricing Program

Senate appropriators pass HHS spending bill that includes 340B Drug Pricing Program user fee and instructions to HRSA to consider stakeholder input in final mega-guidance.

view more »
340B Drug Pricing Program

The decision follows the pharmaceutical company's recent recalculation of 340B ceiling prices for 25 products for the third quarter of 2012 through the second quarter of 2013.

view more »
340B Drug Pricing Program

In new Modern Healthcare commentary, America's Essential Hospitals president and CEO says proposed guidance conflicts with HHS goals for readmissions, access, and care coordination.

view more »
340B Drug Pricing Program

A 2015 budget law that creates site-neutral payment for off-campus hospital outpatient departments does not directly affect 340B Drug Pricing Program eligibility, but changes to how hospitals report Medicare costs does raise concerns.

view more »
340B Drug Pricing Program

Final rule and implementation as described in the guidance could significantly reduce Medicaid payments for 340B-covered outpatient drugs in some states.

view more »
340B Drug Pricing Program

Webcasts, co-hosted by HRSA OPA and pharmacist association, will focus on helping covered entities identify steps needed to develop and maintain comprehensive 340B policies and procedures in an auditable manner.

view more »
340B Drug Pricing Program

Covered entities are no longer required to post a public letter to the HRSA website if 340B audit findings result in potential repayment. Instead, HRSA will publish notices with covered entity contact information.

view more »
340B Drug Pricing Program

Association expresses deep disappointment with Medicare Payment Advisory Commission (MedPAC) recommendation to cut Medicare Part B reimbursement to hospitals in the 340B Drug Pricing Program.

view more »
340B Drug Pricing Program
340B Drug Pricing Program

Agency seeks comment on its proposal to collect information on the burden associated with guidelines for manufacturer audits of covered entities; comments are due to HRSA by Feb. 22.

view more »
340B Drug Pricing Program

Association generally supports move toward patient-centered care, but urges CMS to ensure provisions do not place an administrative burden on hospitals.

view more »
340B Drug Pricing Program

Join us to review our 2015 federal legislative and regulatory action and preview our 2016 advocacy agenda.

view more »
340B Drug Pricing Program

Member leaders attend more than 100 meetings with lawmakers and congressional staff as part of fall Policy Assembly. Event also included insights from policymakers and a Capitol Hill reception honoring 2015 Gage Award recipients.

view more »
340B Drug Pricing Program

In comments to HRSA, the association says the proposal would harm care for the vulnerable by restricting the definition of a patient, adding requirements for hospital outpatient facility eligibility, and narrowing which drugs qualify for discounts.

view more »
340B Drug Pricing Program

U.S. District Court says 2014 HRSA interpretive rule is contrary to plain language of ACA provision that excludes certain hospitals from 340B discounts on orphan drugs.

view more »
340B Drug Pricing Program

Webinars help identify roles, responsibilities, and other elements of 340B risk management. OPA and APhA also accepting leading practice site applications.

view more »
340B Drug Pricing Program

Zydus Pharmaceuticals Inc., charged incorrect rates on 340B drugs between January 2012 and December 2014. Refunds will be distributed via Apexus.

view more »
340B Drug Pricing Program